Gore receives FDA approval for the GORE TAG conformable thoracic stent graft with ACTIVE CONTROL

Huge Two-Day Clean Sweep Auction July 24-25th. Click Here to Bid!

advertisement
Posição atual:
>
>
> This Story

Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Cardiology Homepage

Abbott receives U.S. approval of next-generation MitraClip, bringing new enhancements to Abbott's leading MitraClip platform

Telehealth Technology to reduce hospital readmissions and improve outcomes for cardiac disease patients

FDA approves Bayer's Gadavist (gadobutrol) injection as first contrast agent for use in cardiac MR in adult CAD patients

New technology improves atrial fibrillation detection after stroke

New study of ultrasound enhancing agents in echocardiography reaffirms safety profile of LUMASON

Johns Hopkins Medicine researchers identify health conditions likely to be misdiagnosed

Team approach to cardiac care increases chance of surviving heart attack complications

Philips supports CNIC to shape the future of cardiac care

Cardiac arrest among hospitalized patients may be underestimated

RAPID receives registration approval in Japan

Gore receives FDA approval for the GORE TAG conformable thoracic stent graft with ACTIVE CONTROL

Press releases may be edited for formatting or style
FLAGSTAFF, Ariz.--(BUSINESS WIRE)--W. L. Gore & Associates, Inc. (Gore) today announced that the U.S. Food and Drug Administration (FDA) has granted regulatory approval for commercial distribution for the GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System, a unique Thoracic Endovascular Aortic Repair (TEVAR) solution combining new levels of control with the proven legacy and trusted performance of the Conformable GORE® TAG® Device. The device and delivery system provide new precision and predictable patient outcomes in the endovascular repair of aneurysms, transections, and Type B dissections of the descending thoracic aorta. A smaller-diameter primary delivery sleeve gives the device and system a lower profile across 10 device sizes.

The GORE® ACTIVE CONTROL System provides controlled, two-stage deployment, with primary deployment to an intermediate diameter and a secondary deployment to full diameter. This design allows for continuous blood flow throughout the deployment with multiple opportunities to visualize and refine graft placement. It is also designed to allow for angulation of the proximal end of the device for improved seal and apposition. It gives physicians added precision in placement and angulation so they can take full advantage of the exceptional conformability of the Gore device and confidently provide a minimally-invasive solution to more patients.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



No change was made to the stent graft itself, which, as the world’s most-studied* TEVAR device, has demonstrated long-term freedom from device-related reintervention (93.1%) and low complication rates (zero migrations, fractures, or compressions).** Large device oversizing windows were engineered, tested, and proven to accommodate differences in proximal and distal landing zone diameters; a unique 6% to 33% oversizing window allows physicians to choose the optimal radial force to fit patient anatomy and etiology, whether treating a young trauma patient or a fragile dissected aorta. The 16mm to 42mm range can be treated with as few as five sizes, allowing providers to stock fewer devices while treating a broader range of patients.

“The GORE® TAG® Device family has a legacy of trusted performance and durability, and we knew we could build on that by enhancing control during deployment, which would help make TEVAR procedures more predictable for physicians,” said Eric Zacharias, a vascular business leader at Gore. “Physicians can now deploy our thoracic stent graft in the descending thoracic aorta with more operative ease, even in those patients with challenging angulated aortic arches, and meet the clinical and practical challenges of TEVAR with confidence. With this latest product iteration, Gore is continuing its unparalleled commitment to developing solutions that advance endovascular solutions for diseases of the aorta.”
  Pages: 1 - 2 >>

Cardiology Homepage


You Must Be Logged In To Post A Comment